コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 60 mg/m(2) on days 1, 3, and 5 combined with cytosine arabinoside.
2 t occur after treatment with doxorubicin and cytosine arabinoside.
3 n organotypic cerebellar cultures exposed to cytosine arabinoside.
4 any of these drugs) or greater than 7.5 g of cytosine arabinoside.
5 25 mg/m2/d IV CI over 24 hours, days 1 to 4; cytosine arabinoside 1.5 g/m2/d IV over 2 hours on day 5
6 ed in significantly increased sensitivity to cytosine arabinoside, accompanied by significantly decre
7 tively sensitive to cytotoxic agents such as cytosine arabinoside and 5-fluorouracil but MIP-1alpha c
9 ion synergistically enhanced cytotoxicity of cytosine arabinoside and doxorubicin in AML blasts but n
10 l to a chemotherapeutic induction regimen of cytosine arabinoside and idarubicin hydrochloride, with
11 olus at 50 mg/m(2) daily 3 times followed by cytosine arabinoside and mitoxantrone (FLAM) is active i
13 chemotherapeutic agents (i.e. methotrexate, cytosine arabinoside and thio-TEPA) administered by a va
14 the presence of the DNA synthesis inhibitor cytosine arabinoside and transfected with plasmids conta
16 , as evidenced by blocking neurogenesis with cytosine arabinoside, and helps to preserve the hippocam
17 drol = methylprednisolone, High-dose Ara-C = cytosine arabinoside, and Platinum = cisplatinum), in a
18 ed by AG1295 was compared to the response to cytosine arabinoside (Ara C) and correlated with the pre
19 ed in vitro sensitivity of DS myeloblasts to cytosine arabinoside (ara-C) and daunorubicin and the gr
21 y 5'-phosphonate derivatives of cytidine and cytosine arabinoside (ara-C) have been prepared via phos
23 to those with non-DS AML, linked to greater cytosine arabinoside (ara-C) sensitivity and higher tran
24 an display de novo or acquired resistance to cytosine arabinoside (Ara-C), a primary component of ind
25 of intracerebroventricular (ICV) infusion of cytosine arabinoside (Ara-C), an inhibitor for cell prol
26 -amino-5'-phosphono derivatives of cytidine, cytosine arabinoside (ara-C), and uridine have been prep
27 n of INPP4B conferred leukemic resistance to cytosine arabinoside (ara-C), daunorubicin, and etoposid
28 r in vitro treatments with daunomycin (DNR), cytosine arabinoside (ARA-C), or gamma irradiation (RAD)
29 comparison to the standard chemotherapy drug cytosine arabinoside (Ara-C), PTL is much more specific
30 omal cells, exhibited up to 1.7-fold reduced cytosine arabinoside (ara-C)-induced apoptosis, compared
33 ight in response to the active metabolite of cytosine arabinoside (ara-C, cytarabine), ara-CTP, has b
35 nduction chemotherapy regimens consisting of cytosine arabinoside (Ara-C; A), daunorubicin (D), and e
39 The cells were then treated with either beta-cytosine arabinoside (araC) or caffeine, and chromatid b
41 ibition of DNA synthesis with hydroxyurea or cytosine arabinoside (AraC) triggers a concerted repress
42 cephalic neurons, we compared the effects of cytosine arabinoside (AraC), a known neuronal apoptosis
43 sensitivity experiments with 5-fluorouracil, cytosine arabinoside (araC), and mercaptopurine (MP) dem
44 has been found by others that treatment with cytosine arabinoside (araC), but not aphidicolin, can al
45 1/S boundary were treated with pro-apoptotic cytosine arabinoside (araC), PP1alpha protein increased
47 utyl hydroperoxide or the anti-cancer agents cytosine arabinoside, bleomycin, melphalan, and cis-dich
48 chemotherapeutic agents [i.e. methotrexate, cytosine arabinoside (both free and liposomal) and thio-
50 osphamide alone) or intensive (mitoxantrone, cytosine arabinoside, cyclophosphamide) priming on the c
51 ycles with high-dose methotrexate, high-dose cytosine arabinoside, cyclophosphamide, etoposide, ifosp
52 bine (2',2'-difluorodeoxycytidine, dFdC) and cytosine arabinoside (cytarabine, ara-C) represent a cla
53 (FLA) with standard chemotherapy comprising cytosine arabinoside, daunorubicin, and etoposide (ADE).
54 tected the BFU-e's from apoptosis induced by cytosine arabinoside, demonstrating that the SP600125 in
56 in synthesis during a synchronous infection, cytosine arabinoside had no effect at concentrations suf
57 (ATRA) plus an anthracycline with or without cytosine-arabinoside has yielded complete response rates
58 derivatives of the nucleosides cytidine and cytosine arabinoside have been prepared from the corresp
59 O with or without IL-11 with idarubicin plus cytosine arabinoside (IA), as previously administered, i
61 N-alpha, as well as that of HHT and low-dose cytosine arabinoside in patients failing IFN-alpha thera
62 ion of ARC promoted apoptosis and sensitized cytosine arabinoside-induced apoptosis in OCI-AML3 cells
63 nders human leukemic cells more resistant to cytosine arabinoside-induced apoptosis, whereas knockdow
64 lineage kinase inhibitor CEP-1347 prevented cytosine arabinoside-induced neuronal death, demonstrati
65 optosis of immature granule cells induced by cytosine arabinoside is not inhibited by the Egr inhibit
67 to genotoxic agents including etoposide and cytosine arabinoside, MEKK1 is cleaved at Asp874 by casp
69 tuzumab conditioning (carmustine, etoposide, cytosine arabinoside, melphalan, and alemtuzumab 10 mg/d
70 at treatment of HL60 cells with etoposide or cytosine arabinoside or treatment of breast epithelial c
71 es and, when combined with either ABT-737 or cytosine arabinoside, provided substantial therapeutic b
72 n agreement with PI3K/AKT as an effector for cytosine arabinoside resistance in acute myeloid leukemi
73 rther, a PI3-kinase inhibitor, LY294002, and cytosine arabinoside synergized in antileukemia effects
74 th induced by potassium deprivation, but not cytosine arabinoside, we asked whether the Egr inhibitor
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。